These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab].
    Author: Gong LH, Liu WF, Ding Y, Zhang W, Yang YK, Yu F, Wong GQ, Huang XY, Niu XH.
    Journal: Zhonghua Bing Li Xue Za Zhi; 2018 Jun 08; 47(6):449-454. PubMed ID: 29886590.
    Abstract:
    Objective: To investigate the radiological and histopathological features of giant cell tumor of bone treated with RANKL inhibitor denosumab. Methods: Eleven cases were retrieved from the surgical pathology records between March 2015 and June 2017 in Beijing Jishuitan Hospital. Formalin fixed, paraffin embedded specimens were collected and the histological features were evaluated. The imaging features including X ray, magnetic resonance imaging, and computed tomography were also reviewed. Results: These 11 cases of giant cell tumor of bone were derived from five female and six male patients, with age ranged from 20 to 62 years (mean age, 35 years). The tumors were located in the sacrum (6 cases), femur (2 cases), radius (1 case), tibia (1 case) and patella (1 case), respectively. Histologically, all cases showed depletion of giant cells, proliferation of mononuclear cells and different degrees of ossification 3 to 6 months after denosumab therapy. Radiography showed marked osteosclerosis and sclerotic rim formation. Three cases of the sacrum recurred after 5, 6 and 11 months of surgery, and the remaining cases showed no recurrence within follow-up of 1 to 14 months. Conclusions: Denosumab treated giant cell tumors morphologically differ from untreated tumors. Careful attention to a history of denosumab administration is crucial to avoid misdiagnosis and to allow proper differentiation from other tumors and tumor-like lesions. 目的： 探讨核因子κB受体活化因子配体(receptor activator of nuclear factor kappa－B ligand, RANKL)抑制剂denosumab治疗前后骨巨细胞瘤的临床影像学特征、组织学形态、诊断及鉴别诊断要点。 方法： 回顾性分析2015年3月至2017年6月11例就诊于北京积水潭医院、术前经denosumab治疗的骨巨细胞瘤病例资料，分析治疗前后影像学及组织学形态改变。 结果： 女性5例，男性6例，年龄20～62岁，平均年龄35岁。骶骨6例，股骨2例，桡骨、胫骨及髌骨各1例。经denosumab治疗3～6个月后，肿瘤组织学上表现为巨细胞减少甚至消失；单一性的梭形细胞增生伴不同程度的纤维化或新骨形成，骨的形态可以是幼稚的骨样基质、编织状骨及较成熟的板层骨。影像学上显示显著的骨硬化，病变周边的硬化缘形成。3例发生于骶骨的患者分别于术后5、6、11个月复发，其余术后经随访1～14个月未见复发。 结论： 经denosumab治疗后，骨巨细胞瘤组织形态与原病理表现截然不同，应与一些良性及恶性的骨肿瘤及肿瘤样病变相鉴别。denosumab治疗时间与形态学表现及复发情况的关系仍需进一步观察。.
    [Abstract] [Full Text] [Related] [New Search]